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Winter mortality in elderly people in Britain
Action on outdoor cold stress is needed
to reduce winter mortality
Editor—The paper by Wilkinson et al, on
people aged over 75, makes a useful
addition to the evidence that winter mortal-
ity in Britain is now not caused primarily by
deprivation and failure to heat homes.1 In
addition to other evidence they quote, a
recent study on younger people provides
positive indications that cold exposure
outside the home causes winter mortality
regardless of economic status.2
Manual workers (social class 5) of work-
ing age (50–59) in Britain had low cold
related mortality compared with any other
class. This was not the case with their wives
of similar age or for men of the same class
after retirement age (65–74). It implies that
internal heat production from manual work
protected class 5 men of working age against
daytime cold stress and consequent mortal-
ity. Elderly people in sheltered housing that
was fully heated, but who often went
outdoors, had as much winter mortality as
the general elderly population.3
Despite considerable evidence, reduc-
tion of outdoor cold stress has been largely
ignored in official campaigns to control win-
ter mortality. Heating of waiting areas for
public transport, and at least windproof
shelters on bus routes subject to unsched-
uled delays, are obvious measures that
would help. Another is to broadcast warn-
ings when cold weather is forecast, that
dressing warmly, with hats and with wind-
proofs and waterproofs when necessary, can
prevent not only discomfort but often illness
and death. To keep moving while outdoors is
also important.
Surveys in Europe and Siberia provided
statistical evidence that such behaviour,
as well as warm homes, is associated with
low winter mortality.4 5 We have found
advice on these lines to avoid outdoor cold
stress, given via the media, well received by
elderly people, provided that they are also
given the evidence that outdoor cold
accounts for much of Britain’s winter
mortality.
William R Keatinge emeritus professor
Queen Mary College, University of London,
London E1 4NS
w.r.keatinge@qmul.ac.uk
Gavin C Donaldson lecturer in respiratory medicine
Barts and the London School of Medicine and
Dentistry, Queen Mary College
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Outdoor exposure and effect of windchill
should be taken into consideration
Editor—The study by Wilkinson et al,
reporting a lack of effect socioeconomic
gradient on excess winter
mortality, contributes much
to the debate seeking the
best means to address this
major public health issue.1
Currently, the UK govern-
ment make a substantial
financial payment to elderly
people, the “winter fuel pay-
ment,” in an attempt to
address fuel poverty, but it is
becoming increasingly clear
that other personal factors,
such as outdoor exposure to
low temperature, may play a
large part in determining
risk.
I have two hypothetical questions.
Firstly, could the excess mortality in
women be related to their being more likely
to spend time outdoors in low temperatures,
as in this age group it is still likely that they
would bear the brunt of domestic tasks such
as shopping?
Secondly, does the measure of air
temperature used accurately reflect the tem-
perature experienced by the individual,
given that windchill is a major component of
environmental exposure? If the data were
re-analysed to include windchill effects for
each region, how would this affect results?
Alan A Woodall specialist registrar in public health
medicine
Telford and Wrekin Primary Care Trust, Telford
TF1 5RY
alan.woodall@shropshireha.wmids.nhs.uk
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Lack of social gradient in winter excess
mortality is obvious in Denmark
Editor—Despite smaller fluctuations in
seasonal mortality in general,1 2 we obtained
similar results for our analysis of excess
winter mortality in Denmark to those that
Wilkinson et al found for Britain3: an
increase of seasonality with age, higher
excess winter mortality for women—
especially for respiratory diseases—and a
lack of a social gradient related to mortality
in winter.
Our analysis used Danish register data
and was based on all women and men aged
65 and older in Denmark between 1980
and 1998. These 1.8 million people
survived on average about 100 months dur-
ing the observation period (186 271 440
person months lived). Using logistic regres-
sion, we obtained the follow-
ing results: the odds ratios
showed that winter mortality
from all causes was 17.9%
higher for women and 15.7%
higher for men than during
summer. The disadvantage
of women was even more
pronounced for respiratory
diseases, with an excess of
55.4% (men: 36.5%). The
increase of seasonality with
age was similar for women
and men until the age group
85-89 years. At higher ages,
men surpassed women in
excess winter mortality. We could not detect
any social gradient in vulnerability to excess
winter mortality—regardless of whether
socioeconomic status was measured as
highest completed education or wealth on
the family level. We found, however, that
people living alone faced higher excess
winter mortality than women and men who
shared their household with at least one
more person.
Our results thus support the findings of
Wilkinson et al that fighting fuel poverty
might not significantly reduce the annual,
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cold related death toll.3 Policies aimed at
reducing winter excess mortality as sug-
gested by Keatinge et al should aim at all
elderly people, in particular women and
people who are living alone.4
Roland Rau PhD student
Max Planck Institute for Demographic Research,
18057 Rostock, Germany
rau@demogr.mpg.de
Competing interests: None declared.
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Author’s reply
Editor—Keatinge and Donaldson and
Woodall point out the important evidence
that winter and cold-related mortality may
be caused by outdoor exposures to cold. We
strongly support their view that to date pub-
lic health strategies to reduce winter mortal-
ity have paid insufficient attention to
reducing outdoor cold stress.
However, our study on winter death in
elderly people should not be interpreted as
providing evidence against indoor tempera-
tures as important. The results have little
bearing on this and are entirely compatible
with indoor cold as an important or even
dominant factor. Inadequate home heating
remains a probable key determinant of
winter death.
Our conclusion that tackling fuel pov-
erty may be insufficient reflects the simple
observation that the risk of excess winter
death seems to be widespread, and not sim-
ply concentrated in the poorer socioeco-
nomic groups targeted by fuel poverty
strategies. Intuitively, a lack of socioeco-
nomic gradient might seem contrary to the
expected distribution of cold homes, but it is
in fact consistent with limited evidence that
low indoor temperatures are not confined to
poor households.1 Cold exposure through
such activities as standing at an unshielded
bus stop might also be expected to have a
socioeconomic gradient, so the lack of one,
which Rau also reports in an analysis of
Danish data, points to a more complex
distribution of risk.
Woodall’s conjectures on the impor-
tance of windchill and the activity patterns
of women are interesting, and remind us
that there remain many questions about
determinants and mechanisms.
Paul Wilkinson senior lecturer
London School of Hygiene and Tropical Medicine,
London WC1E 7HT
Paul.Wilkinson@lshtm.ac.uk
Competing interests: None declared.
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Bioterrorism and compulsory
vaccination
United States continues vaccinating to
keep troops healthy
Editor—Jefferson questions military use of
anthrax and smallpox vaccines licensed as
safe and effective by the US Food and
Drug Administration (FDA).1 The Depart-
ment of Defense is concerned about the
safety of US service members, so we
vaccinate them to keep them healthy. Vacci-
nation provides the only round the clock
protection against the malicious use of
microbes as weapons.
Our vaccination programmes are based
on a credible military threat, recognised by
multiple government agencies and adminis-
trations. Given that a few cubic metres could
hide a grievous quantity of anthrax spores
or variola virus, the unsuccessful hunt for
weapons of mass destruction in Iraq has
done little to reassure us. That anthrax and
smallpox infections are not circulating natu-
rally is irrelevant when these microbes can
be targeted wilfully at our troops. Anthrax
spores are all too easy to deliver, as our
nation learnt in fall 2001.
The values of anthrax vaccine and small-
pox vaccine are established in the medical
literature, which is more extensive and more
accurate than cited in the editorial. The
National Academy of Sciences published a
comprehensive review of anthrax vaccine
safety and efficacy in March 2002.2 The FDA
recently affirmed that human and animal
evidence show that anthrax vaccine protects
regardless of route of exposure.3 The
modern military safety surveillance system
first identified the rare risk of myopericardi-
tis after smallpox vaccination,4 something
otherwise unrecognised in America, and
then described the extent of recovery from
this condition.5 The rigorous screening pro-
gramme adopted in the US civilian and
military smallpox vaccination programmes
resulted in serious adverse event rates at or
below historical expectations.w1 w2
Until improved vaccines are licensed we
will not risk our troops’ lives against lethal
biological weapons. We use today’s vaccines
to shield our service members so they can
succeed in their mission to protect our
nation, and return home healthy.
John D Grabenstein deputy director
Military Vaccine Agency, 5113 Leesburg Pike, Suite
402, Falls Church, VA 22041 USA
john.grabenstein@us.army.mil
William Winkenwerder Jr assistant secretary of
defense (health affairs)
Washington, DC, USA
Competing interests: None declared.
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Author’s reply
Editor—Winkenwerder and Grabenstein
question the scientific basis of my editorial. I
repeat my statement that the only available
field evidence in humans comes from a
badly reported 1950s trial of a vaccine simi-
lar to adsorbed anthrax vaccine (AVA). This
vaccine was probably effective against
cutaneous anthrax but the researchers
specifically concluded that no such claims
could be made regarding inhalation
anthrax.
The Institute of Medicine report cited by
Winkenwerder and Grabenstein concludes
that such evidence exists as follows:
“Finding: The committee finds that the
available evidence from studies with humans
and animals, coupled with reasonable
assumptions of analogy, shows that AVA as
licensed is an effective vaccine for the
protection of humans against anthrax,
including inhalational anthrax, caused by
any known or plausible engineered strains
of B anthracis.”1
In other words, as I said in my editorial,
currently no field evidence exists of AVA’s
effectiveness against inhalation anthrax in
humans. In my view no amount of political
window dressing can change this fact.
Winkenwerder and Grabenstein believe
that laboratory evidence from animals and
humans using surrogate outcomes such as
antibody responses coupled with “reason-
able assumptions” are enough to justify
forced vaccination of 2.4 million souls.
It is unclear to me whether informed
consent is being obtained from military per-
sonnel prior to immunisation and if so on
what basis. As evidence from field trials is
lacking it seems that US military personnel
are being used as involuntary guinea pigs.
I also note that neither author has
declared competing interests. Does being
politically responsible for an immunisation
programme not create a conflict of interest
when the basis for decision making is
questioned?
Tom Jefferson coordinator
Cochrane Vaccines Field, Via Adige 28a, 00061
Anguillara Sabazia, Rome, Italy
toj1@aol.com
I thank Enrico Materia for his help with my editorial.
Content and opinions remain my sole responsibility.
Competing interests: None declared.
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Arguments for current vaccines are based
on inadequate support for older vaccines
Editor—Jefferson discussed some of the
major flaws of the study by Brachman et al
with respect to policies making certain
vaccines compulsory in the US military.1 2
Additional shortcomings of the study by
Additional references w1 and w2 are on bmj-
.com
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Brachman et al have been described in fuller
detail elsewhere.3–5 For example, the often
reported rate of 92.5% effectiveness for the
anthrax vaccine sounds impressive but
should be considered against the actual
results in which 99.7% (378/379) of
vaccinated workers avoided anthrax infec-
tion compared with 96.4% (399/414) of pla-
cebo workers. Thus the vaccine protected
only an additional 3.3% of workers com-
pared with no treatment.
Moreover, officials from the Department
of Defense continue to ignore criticism of
the 2002 Institute of Medicine report on the
anthrax vaccine.w1 w2 At least three major
studies in England, Canada, and the United
States had found problems with the anthrax
or other vaccines among military veterans.w1
The report mentioned on page 93 some of
those studies but seems to have dismissed
them largely because they were based on self
reports or cross sectional data.w2 Yet, the
same report hails the millennium cohort
study, based largely on self report, as an
important asset for studying the long term
safety of the anthrax vaccine, even though
relatively little information has been asked
about anthrax vaccination in that study.
Furthermore, the RAND Corporation’s
report on immunisations as a factor in Gulf
war illness had been due out in 2002w1 but as
of early October 2004 had not yet been
published. It is not clear why, other than for
political reasons, it would take so long for
the defense department to approve the
release of a scientific text on vaccines and
Gulf war illness, especially when it was being
published by extraordinarily capable and
distinguished scientists affiliated with the
RAND Corporation. Perhaps the best
approach to vaccine education is not to be
found in pretending that certain scientific
results are irrelevant merely because they do
not fit the desired paradigms, political or
otherwise. Given such considerations and
uncertainties, until better evidence is avail-
able, I agree with Jefferson—the choice of
whether to be vaccinated or not should be
left to the individual.
Walter R Schumm professor
School of Family Studies and Human Services,
Kansas State University, Justin Hall, 1700 Anderson
Avenue, Manhattan, KS 66506-1403, USA
Schumm@humec.ksu.edu
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Preventing the spread of
MRSA
All frontline staff need to be involved . . .
Editor—Few would challenge Voss’s asser-
tion that the control of methicillin resistant
Staphylococcus aureus (MRSA) is and will con-
tinue to be of the utmost importance to the
infection control community.1
Yet this assertion contains hidden within
it one of the greatest challenges to be faced
by the infection control community in the
United Kingdom today, for, until the control
of MRSA is of the utmost importance to all
frontline NHS staff, attempts
at control are doomed to
failure. Instilling this simple
truth in the minds of clinical
staff is of the highest priority.
The all too prevalent percep-
tion that MRSA control is
the responsibility and sole
provenance of infection con-
trol professionals is outdated
and if perpetuated will prove
detrimental to achieving
control of MRSA in NHS
hospitals.
Barry A Dale consultant
bacteriologist
Dumfries and Galloway Royal Infirmary, Dumfries
DG1 4AP
B.Dale@dgri.scot.nhs.uk
Competing interests: None declared.
1 Voss A. Preventing the spread of MRSA. BMJ
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. . . the epidemiological nature of the
problem should be tackled . . .
Editor—The attitude towards methicillin
resistant Staphylococus aureus (MRSA) in the
United Kingdom is a case of shutting the
gate after the horse has bolted. Voss says that
in Scandinavia and the Netherlands, where
the prevalence of MRSA is low, a screening
and decolonisation policy for healthcare
workers is advocated.1
My experience of working outside the
United Kingdom (in Australia) was that peo-
ple are unable to work with patients without
being screened and cleared. Having worked
in England in medicine for over 12 years I
have never once been screened. Surely we
should at least be adopting this policy to
help combat the problem?
Patients themselves must shoulder some
of the blame for bringing MRSA into hospi-
tals. It would be a mammoth task to screen
the entire hospital population, but a
staggered approach would be a start.
Screening elective surgical patients before
admission could be the first step, then
perhaps people attending general practice.
I appreciate that in the short term there
is a financial implication (how much and by
whom?) to be considered in screening for
and decolonising MRSA from the general
population. In the long term stopping
MRSA being brought in at the front door, so
reducing lengthy hospital stays, expensive
drug treatment, and potential litigation, will
be more cost effective.
Nicholas Akerman research registrar
St James’s University Hospital, Leeds LS9 7TF
nik_lucy@hotmail.com
Competing interests: None declared.
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. . . and the role of practices such as
phlebotomy is worth considering
Editor—The spread of methicillin resistant
Staphylococcus aureus (MRSA) has been
wholly apportioned by the mass media to
poor handwashing tech-
niques by doctors and
nurses.1 Although handwash-
ing techniques must be
improved, other quite blatant
modes of transmission are
swept aside.
Every healthcare profes-
sional will be aware of the
prevalence of MRSA in the
community, yet the media
never consider that the rela-
tives and friends of patients
may well be an important
factor in the spread of MRSA
in the hospital setting. However, after
observing phlebotomists at work I have
come to realise a far more obvious mode of
transmission—the tourniquet.
No junior doctor would be without
phlebotomists, who make the busy house
officer’s working life so much easier. They
graciously attend all the wards in the hospi-
tal and thanklessly take blood. In doing this
however, they may well be giving MRSA the
helping hand it needs. The same tourniquet
is used on all the patients on all the wards
throughout the hospital, no doubt ensuring
a spread of MRSA throughout. To overcome
this risk of transmission the tourniquet must
be disposed of after each use.
During my training I was always taught
not to use a glove as a tourniquet for fear of
leaving it on the patient. However, the glove
does provide a cheap, easily accessible, and,
most importantly, disposable tourniquet that
may well help cut down the transmission
rates of MRSA in hospitals.
Although this seems quite a simple idea,
I believe simple techniques will help reduce
transmission rates of MRSA nationwide.
Frank J Conroy senior house officer, plastic surgery
Pinderfields Hospital, Wakefield WF2 4DG
drfrank77@yahoo.co.uk
Competing interests: None declared.
1 Wilson P. The tabloid fixation on superbugs. BMJ
2004;329:578. (4 September.)
SO
UT
HA
M
PT
O
N
G
EN
ER
AL
H
O
SP
IT
AL
/S
PL
Additional references w1 and w2 are on
bmj.com
Letters
978 BMJ VOLUME 329 23 OCTOBER 2004 bmj.com
Treatment of impetigo
Paint it blue
Editor—Koning and van der Wouden in
their editorial on treatment of impetigo dis-
cuss the relative merits of systemic and topi-
cal antibiotics that were reported in their
recent Cochrane review and add that they
have no evidence to support the therapeutic
value of disinfecting agents, which they note
have hardly been studied.1 They comment
that studies establishing the value of
disinfecting agents are therefore most
welcome.
Generations of general practitioners have
treated impetigo with gentian violet, and
although there has been some trial evidence
that its effectiveness extends to methicillin
resistant Staphylococcus aureus,2 the main
support for its use is clinical experience
passed on from one practitioner to the next
and reinforced by the rapid resolution they
see when failures with more cosmetically
acceptable topical antibiotic preparations
lead to a trial of gentian violet.
The processes developing evidence
based practice must be able to promote
those treatments that have been reliably
proved while somehow preventing the loss
of longstanding effective remedies for which
there will never be a commercial imperative
to fund trials. Surveys that aggregate the col-
lective experience of practitioners and iden-
tify treatments that are perceived as effective
but have not been evaluated should trigger
investigation, perhaps through the health
technology assessment route, rather than
lead to abandoning the treatment and send-
ing another baby down the plug hole with
the bath water.
For those who might be stimulated by
this letter to try gentian violet for impetigo,
the agent must be kept away from the
cornea.3
Roderic S MacDonald specialist in musculoskeletal
medicine
London W4 2NL
rodmacdonald@blueyonder.co.uk
Competing interests: None declared.
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Save mupirocin
Editor—Koning and van der Wouden write
that guidelines may contain policies to
reserve certain antibiotics for the treatment
of other, more serious infections.1 For exam-
ple, systemic fusidic acid is considered to be
crucial in treating severe bone infections,
and mupirocin is a cornerstone in eradicat-
ing the carriage of methicillin resistant
Staphylococcus aureus (MRSA).
The Swedish Medical Products Agency
would probably agree. It recommended that
Swedish doctors and nurses should use nei-
ther fusidic acid nor mupirocin topically.
Fusidic acid resistant S aureus has rapidly
spread in Sweden, and we in Sweden are
anxious to save mupirocin to help us main-
tain our favourable MRSA situation.
Impetigo should be treated with soap and
water, or with oral antibiotics, according to
the Swedish Medical Products Agency.
Inge Axelsson associate professor
Department of Health Sciences, Mid-Sweden
University, SE-831 25 Ostersund, Sweden
inge.axelsson@mh.se
Competing interests: None declared.
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Health needs of Zimbabweans
are poorly recognised in UK
Editor—In 2002 Zimbabweans were the
second largest group of asylum seekers
coming to the United Kingdom, 7695
asylum applications having been made,1 and
they constitute one of the largest migrant
groups of English speaking peoples from a
developing country for 25 years. The lack of
language barriers may help this community
to use the NHS more effectively than earlier
migrants, but they may face discrimination
nevertheless. What is known, and what
needs to be known about the healthcare
needs of Zimbabweans?
We found that most published work
focuses on HIV and sexual health. The
prevalence of HIV seropositivity in
Zimbabwe is estimated to be 25%. The
proportion of all reported HIV cases in the
United Kingdom acquired in Africa (90%
heterosexually) is over 20% and growing.2
Several factors may pose problems when
treating Zimbabweans with HIV: patients
may present late3 and they are highly mobile
(partly because of the government’s policy
of dispersal for asylum seekers), making fol-
low up and contact tracing difficult. These
problems are not confined to Zimbabweans.
Coinfection with tuberculosis is a major
concern, raising the question of whether
Zimbabwean babies should be vaccinated
with BCG.
In some towns the incidence of HIV has
risen considerably.Many primary care trusts,
local genitourinary services, and individual
general practices are struggling to cope with
increasing demand (our two practices in
Luton together serve over a hundred HIV
positive patients).
However, an inordinate focus on HIV
may divert attention from other health
needs of Zimbabweans. Anxiety, depression,
and mental distress are to be expected
among a population that has suffered rapid
impoverishment and family separation. Peo-
ple have more mundane health problems,
such as hypertension and diabetes. These
have often been poorly controlled, and Zim-
babweans may overlook these if health pro-
fessionals are preoccupied with the risks of
HIV. Only by integrating primary and
specialist care can earlier diagnoses and
improved access be delivered—and the pub-
lic health interests of the whole population
be addressed.
Steve Gillam general practitioner
Lea Vale Medical Group, Luton LU1 1HH
sjg67@medschl.cam.ac.uk
Raj Khanchandani general practitioner
Biscot Road Surgery, Luton LU3 1AH
Melusi Ndebele specialist in sexual health promotion
and African communities
Luton Teaching Primary Care Trust, Luton
LU1 1JD
Competing interests: None declared.
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zimbabwe.htm (accessed 22 Sep 2004).
2 Sinka K, Mortimer J, Evans B, Morgan D. Impact of the
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ing and high risk sexual behaviour among London’s
migrant African communities: a participatory research
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Private sector needs incentives
for AIDS vaccine
Editor—Tucker and Mazithulela are right
to identify the need to increase involvement
of the private sector in the quest for a
preventive vaccine for HIV/AIDS.1 Pharma-
ceutical companies are best placed to come
up with vaccines and crucial new treatments
for AIDS and other conditions for which no
treatment exists, but as the major markets
for such products are the poorest countries
on the planet, there is little likelihood of a
reasonable return on investment.
We therefore need to develop incentives
that will bring the private sector into the hunt
for a vaccine; these may include tax incentives
on vaccine research, guaranteed volume sales,
tiered pricing alongside anti-reimportation
measures, public and intergovernment subsi-
dies and philanthropic donations, and per-
haps patent extensions could be offered on
other products.
Big Pharma needs such carrots if it is to
commit to HIV/AIDS busting vaccine
research and development, rather than
being damned if they do and damned if they
don’t—the current activist approach.
Another problem remains: the trickle-
down pattern whereby product develop-
ment is followed by the recouping of costs
through profits in industrialised countries,
after which prices drop and become afford-
able in poor countries decades later, is not
viable for HIV/AIDS.
The rapid transport to and effective dis-
tribution of doses to the depths of
sub-Saharan Africa—where about 27 million
are living with HIV, and presenting a risk to
countless millions of others—will take
unprecedented commitment from and
cooperation between civil society, which
includes the private sector, and politicians.
Benedict Irvine director, health projects
International Policy Network, London WC2E 8HA
ben@policynetwork.net
Competing interests: None declared.
1 Tucker TJ, Mazithulela G. Development of an AIDS
vaccine: perspective from South African AIDS Vaccine
Initiative. BMJ 2004;329:454-6. (21 August.)
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